{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T14:52:25Z","timestamp":1781621545267,"version":"3.54.5"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T00:00:00Z","timestamp":1764028800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T00:00:00Z","timestamp":1764028800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Fogarty International Centre and National Heart, Lung & Blood Institute of the National Institutes of Health","award":["D43 TW010345"],"award-info":[{"award-number":["D43 TW010345"]}]},{"name":"Fogarty International Centre and National Heart, Lung & Blood Institute of the National Institutes of Health","award":["D43 TW010345"],"award-info":[{"award-number":["D43 TW010345"]}]},{"name":"Fogarty International Centre and National Heart, Lung & Blood Institute of the National Institutes of Health","award":["D43 TW010345"],"award-info":[{"award-number":["D43 TW010345"]}]},{"name":"Fogarty International Centre and National Heart, Lung & Blood Institute of the National Institutes of Health","award":["D43 TW010345"],"award-info":[{"award-number":["D43 TW010345"]}]},{"name":"Fogarty International Centre and National Heart, Lung & Blood Institute of the National Institutes of Health","award":["D43 TW010345"],"award-info":[{"award-number":["D43 TW010345"]}]},{"name":"Fogarty International Centre and National Heart, Lung & Blood Institute of the National Institutes of Health","award":["D43 TW010345"],"award-info":[{"award-number":["D43 TW010345"]}]},{"name":"Fogarty International Centre and National Heart, Lung & Blood Institute of the National Institutes of Health","award":["D43 TW010345"],"award-info":[{"award-number":["D43 TW010345"]}]},{"name":"Fogarty International Centre and National Heart, Lung & Blood Institute of the National Institutes of Health","award":["D43 TW010345"],"award-info":[{"award-number":["D43 TW010345"]}]},{"DOI":"10.13039\/100001009","name":"Bristol Myers Squibb Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001009","id-type":"DOI","asserted-by":"publisher"}]},{"name":"the BLOODSA Foundation"},{"DOI":"10.13039\/501100001325","name":"Cancer Association of South Africa","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001322","name":"South African Medical Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001322","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Classic Hodgkin Lymphoma (cHL) is a highly curable cancer disproportionately affecting younger patients and those with human immunodeficiency virus (HIV) infection. In under-resourced regions with endemic HIV or tuberculosis, cHL treatment outcomes are poor when compared to high-income settings for numerous disease, patient and health systems related factors. Over 80% of patients present with advanced disease and reducing diagnosis delays is thought to be critical in improving survival. However, because early-stage cHL is relatively uncommon in these settings, data evaluating outcomes in patients with early-stage disease are lacking.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Method<\/jats:title>\n                    <jats:p>This retrospective study examined 70 patients with early-stage cHL. These patients, derived from a consecutive cohort of 387 cHL patients treated between 2010 and 2022, were meticulously staged with the Modified Lugano staging system and positron emission tomography \/ computed tomography (PET\/CT). Progression-free survival (PFS), overall survival (OS), and the applicability of National Comprehensive Cancer Network (NCCN) risk stratification were assessed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The median age at diagnosis was 35 years and most patients had stage II (86%), or unfavourable disease (76%). The 5-year OS for the favourable and unfavourable groups were similar (94% vs. 90%,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.599) as was 5-year PFS (83% vs. 88%,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.984). Five-year OS for the HIV positive patients was 94% and 90% in HIV negative patients (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.684), and PFS was 100% and 82%, respectively (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.086).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This study demonstrated survival outcomes in early-stage cHL patients comparable with higher income countries, notwithstanding HIV status or unfavourable NCCN classification. In contrast to the previous study from our centre which showed overall survival rates of 66%, for patients with cHL of all disease stages, we highlight the importance of facilitating early diagnosis and treatment in low- and middle-income countries.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12885-025-15219-0","type":"journal-article","created":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T09:59:18Z","timestamp":1764064758000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Early-stage Hodgkin lymphoma in Cape Town, South Africa: prognostic risk factors at diagnosis and treatment outcomes"],"prefix":"10.1186","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-4519-9398","authenticated-orcid":false,"given":"Shakira","family":"Dawood","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-0623-6343","authenticated-orcid":false,"given":"Brigid","family":"McMillan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6132-4717","authenticated-orcid":false,"given":"Karryn","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7181-3015","authenticated-orcid":false,"given":"Jenna","family":"Oosthuizen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-6453-9173","authenticated-orcid":false,"given":"David","family":"Richardson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1829-154X","authenticated-orcid":false,"given":"Kudakwashe","family":"Simba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8608-6233","authenticated-orcid":false,"given":"Lillian F.","family":"Andera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1408-2604","authenticated-orcid":false,"given":"Jessica","family":"Opie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9000-5504","authenticated-orcid":false,"given":"Katherine","family":"Antel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6957-916X","authenticated-orcid":false,"given":"Stuart","family":"More","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3376-0992","authenticated-orcid":false,"given":"Ayesha","family":"Allie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4730-4231","authenticated-orcid":false,"given":"Zainab","family":"Mohamed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4657-7318","authenticated-orcid":false,"given":"Estelle","family":"Verburgh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,25]]},"reference":[{"issue":"2","key":"15219_CR1","first-page":"116","volume":"68","author":"S Shanbhag","year":"2018","unstructured":"Shanbhag S, Ambinder RF. Hodgkin lymphoma: A review and update on recent progress. CA Cancer J Clin. 2018;68(2):116\u201332.","journal-title":"CA Cancer J Clin"},{"key":"15219_CR2","doi-asserted-by":"crossref","unstructured":"Momotow J, Borchmann S, Eichenauer DA, Engert A, Sasse S. Hodgkin Lymphoma-Review on Pathogenesis, Diagnosis, current and future treatment approaches for adult patients. J Clin Med. 2021;10(5):1125.","DOI":"10.3390\/jcm10051125"},{"issue":"2","key":"15219_CR3","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1158\/1055-9965.EPI-13-0865","volume":"23","author":"MS Shiels","year":"2014","unstructured":"Shiels MS, Koritzinsky EH, Clarke CA, Suneja G, Morton LM, Engels EA. Prevalence of HIV infection among U.S. Hodgkin lymphoma cases. Cancer Epidemiol Biomarkers Prev. 2014;23(2):274\u201381.","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"12","key":"15219_CR4","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.1002\/ijc.33948","volume":"150","author":"D Singh","year":"2022","unstructured":"Singh D, Vaccarella S, Gini A, De Paula Silva N, Steliarova-Foucher E, Bray F. Global patterns of hodgkin lymphoma incidence and mortality in 2020 and a prediction of the future burden in 2040. Int J Cancer. 2022;150(12):1941\u20137.","journal-title":"Int J Cancer"},{"key":"15219_CR5","doi-asserted-by":"publisher","first-page":"725219","DOI":"10.1155\/2011\/725219","volume":"2011","author":"P Shenoy","year":"2011","unstructured":"Shenoy P, Maggioncalda A, Malik N, Flowers CR. Incidence patterns and outcomes for hodgkin lymphoma patients in the united States. Adv Hematol. 2011;2011:725219.","journal-title":"Adv Hematol"},{"key":"15219_CR6","unstructured":"Institute NC. SEER Program, Cancer stat facts: Leukemia - Acute myeloid leukemia (AML) 2014\u20132018 [Available from: https:\/\/seer.cancer.gov\/statfacts\/html\/amyl.html"},{"issue":"6","key":"15219_CR7","doi-asserted-by":"publisher","first-page":"755","DOI":"10.6004\/jnccn.2020.0026","volume":"18","author":"RT Hoppe","year":"2020","unstructured":"Hoppe RT, Advani RH, Ai WZ, Ambinder RF, Armand P, Bello CM, et al. Hodgkin Lymphoma, version 2.2020, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2020;18(6):755\u201381.","journal-title":"J Natl Compr Canc Netw"},{"issue":"2","key":"15219_CR8","doi-asserted-by":"publisher","first-page":"178","DOI":"10.5152\/balkanmedj.2012.110","volume":"30","author":"S K\u0131l\u0131\u00e7kap","year":"2013","unstructured":"K\u0131l\u0131\u00e7kap S, Bar\u0131\u015fta I, Ulger S, Celik I, Selek U, Y\u0131ld\u0131z F, et al. Clinical features and prognostic factors of hodgkin\u2019s lymphoma: A single center experience. Balkan Med J. 2013;30(2):178\u201385.","journal-title":"Balkan Med J"},{"issue":"12","key":"15219_CR9","doi-asserted-by":"publisher","first-page":"3070","DOI":"10.1093\/annonc\/mdt413","volume":"24","author":"B Klimm","year":"2013","unstructured":"Klimm B, Goergen H, Fuchs M, von Tresckow B, B\u00f6ll B, Meissner J, et al. Impact of risk factors on outcomes in early-stage hodgkin\u2019s lymphoma: an analysis of international staging definitions. Ann Oncol. 2013;24(12):3070\u20136.","journal-title":"Ann Oncol"},{"issue":"10","key":"15219_CR10","doi-asserted-by":"publisher","first-page":"e29219","DOI":"10.1002\/pbc.29219","volume":"68","author":"A Mahajan","year":"2021","unstructured":"Mahajan A, Singh M, Bakhshi S, Jain S, Radhakrishnan V, Verma N, et al. Treating early-stage hodgkin lymphoma in resource-limited settings: InPOG-HL-15-01 experience. Pediatr Blood Cancer. 2021;68(10):e29219.","journal-title":"Pediatr Blood Cancer"},{"key":"15219_CR11","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1200\/GO.20.00391","volume":"7","author":"M Adam","year":"2021","unstructured":"Adam M, Bekueretsion Y, Abubeker A, Tadesse F, Kwiecinska A, Howe R, et al. Clinical characteristics and histopathological patterns of hodgkin lymphoma and treatment outcomes at a tertiary cancer center in Ethiopia. JCO Glob Oncol. 2021;7:277\u201388.","journal-title":"JCO Glob Oncol"},{"key":"15219_CR12","doi-asserted-by":"crossref","unstructured":"Bartlett NL. Limited-stage hodgkin lymphoma: optimal chemotherapy and the role of radiotherapy. Am Soc Clin Oncol Educ Book. 2013;33:374\u201380.","DOI":"10.14694\/EdBook_AM.2013.33.374"},{"issue":"6","key":"15219_CR13","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1002\/cam4.655","volume":"5","author":"M Koshy","year":"2016","unstructured":"Koshy M, Fairchild A, Son CH, Mahmood U. Improved survival time trends in hodgkin\u2019s lymphoma. Cancer Med. 2016;5(6):997\u20131003.","journal-title":"Cancer Med"},{"key":"15219_CR14","doi-asserted-by":"crossref","unstructured":"Patel M, Philip V, Fazel F. Human Immunodeficiency Virus Infection and Hodgkin\u2019s Lymphoma in South Africa: An Emerging Problem. Advances in Hematology. 2011;2011.","DOI":"10.1155\/2011\/578163"},{"key":"15219_CR15","doi-asserted-by":"crossref","unstructured":"Antel K, Levetan C, Mohamed Z, Louw VJ, Oosthuizen J, Maartens G, et al. The determinants and impact of diagnostic delay in lymphoma in a TB and HIV endemic setting. BMC Cancer. 2019;19(1):384.","DOI":"10.1186\/s12885-019-5586-4"},{"issue":"6","key":"15219_CR16","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1111\/bjh.16491","volume":"189","author":"AMJ Reedijk","year":"2020","unstructured":"Reedijk AMJ, Zijtregtop EAM, Coebergh JWW, Meyer-Wentrup FAG, Hebeda KM, Zwaan CM, et al. Improved survival for adolescents and young adults with hodgkin lymphoma and continued high survival for children in the netherlands: a population-based study during 1990\u20132015. Br J Haematol. 2020;189(6):1093\u2013106.","journal-title":"Br J Haematol"},{"key":"15219_CR17","doi-asserted-by":"crossref","unstructured":"Vogt S, Laudin G, Zahurak M, Vaughan J, Lakha A, Pather S, et al. Real-world treatment outcomes for hodgkin lymphoma in South africa: a prospective observational study. Infect Agents Cancer. 2024;19(1):46.","DOI":"10.1186\/s13027-024-00612-4"},{"issue":"4","key":"15219_CR18","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1097\/QAD.0000000000003456","volume":"37","author":"K Antel","year":"2023","unstructured":"Antel K, Oosthuizen J, Brown K, Malherbe F, Loebenberg P, Seaton C, et al. Focused investigations to expedite cancer diagnosis among patients with lymphadenopathy in a tuberculosis and HIV-endemic region. AIDS. 2023;37(4):587\u201394.","journal-title":"AIDS"},{"issue":"2","key":"15219_CR19","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1007\/s00277-018-3533-0","volume":"98","author":"L Swart","year":"2019","unstructured":"Swart L, Novitzky N, Mohamed Z, Opie J. Hodgkin lymphoma at Groote Schuur Hospital, South africa: the effect of HIV and bone marrow infiltration. Ann Hematol. 2019;98(2):381\u20139.","journal-title":"Ann Hematol"},{"issue":"14","key":"15219_CR20","doi-asserted-by":"publisher","first-page":"3417","DOI":"10.1080\/10428194.2020.1815016","volume":"61","author":"K Antel","year":"2020","unstructured":"Antel K, Louw VJ, Maartens G, Oosthuizen J, Verburgh E. Diagnosing lymphoma in the shadow of an epidemic: lessons learned from the diagnostic challenges posed by the dual tuberculosis and HIV epidemics. Leuk Lymphoma. 2020;61(14):3417\u201321.","journal-title":"Leuk Lymphoma"},{"issue":"5","key":"15219_CR21","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1002\/1097-0142(19840901)54:5<885::AID-CNCR2820540522>3.0.CO;2-B","volume":"54","author":"M Tubiana","year":"1984","unstructured":"Tubiana M, Henry-Amar M, Hayat M, Burgers M, Qasim M, Somers R, et al. Prognostic significance of the number of involved areas in the early stages of hodgkin\u2019s disease. Cancer. 1984;54(5):885\u201394.","journal-title":"Cancer"},{"issue":"5","key":"15219_CR22","doi-asserted-by":"publisher","first-page":"361","DOI":"10.7326\/0003-4819-114-5-361","volume":"114","author":"M Henry-Amar","year":"1991","unstructured":"Henry-Amar M, Friedman S, Hayat M, Somers R, Meerwaldt JH, Carde P, et al. Erythrocyte sedimentation rate predicts early relapse and survival in early-stage hodgkin disease. The EORTC lymphoma cooperative group. Ann Intern Med. 1991;114(5):361\u20135.","journal-title":"Ann Intern Med"},{"key":"15219_CR23","doi-asserted-by":"crossref","unstructured":"Mponda M, Kudowa E, Craven DM, Eastburg LC, Chikasema M, Kasonkanji E, et al. Safety, efficacy, and affordability of ABVD for Hodgkin lymphoma in Malawi: a prospective cohort study. eClinicalMedicine. 2024;69:102480.","DOI":"10.1016\/j.eclinm.2024.102480"},{"issue":"1","key":"15219_CR24","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1186\/s12885-024-12569-z","volume":"24","author":"MM Mbai","year":"2024","unstructured":"Mbai MM, Mduma E, Thuo S, Rugengamanzi E, Malichewe CV, Lugina EL. A comparison of clinical profile and treatment outcome of hodgkin\u2019s lymphoma in Tanzania according to HIV status during the HAART era. BMC Cancer. 2024;24(1):796.","journal-title":"BMC Cancer"},{"key":"15219_CR25","doi-asserted-by":"publisher","first-page":"103208","DOI":"10.1016\/j.jbi.2019.103208","volume":"95","author":"PA Harris","year":"2019","unstructured":"Harris PA, Taylor R, Minor BL, Elliott V, Fernandez M, O\u2019Neal L, et al. The REDCap consortium: Building an international community of software platform partners. J Biomed Inf. 2019;95:103208.","journal-title":"J Biomed Inf"},{"issue":"2","key":"15219_CR26","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","volume":"42","author":"PA Harris","year":"2009","unstructured":"Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap) \u2013 A metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2009;42(2):377\u2013831.","journal-title":"J Biomed Inform"},{"issue":"Suppl 4","key":"15219_CR27","doi-asserted-by":"publisher","first-page":"iv19","DOI":"10.1093\/annonc\/mdy080","volume":"29","author":"DA Eichenauer","year":"2018","unstructured":"Eichenauer DA, Aleman BMP, Andre M, Federico M, Hutchings M, Illidge T, et al. Hodgkin lymphoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018;29(Suppl 4):iv19\u201329.","journal-title":"Ann Oncol"},{"issue":"5","key":"15219_CR28","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1111\/bjh.14734","volume":"178","author":"EJ Dann","year":"2017","unstructured":"Dann EJ, Bairey O, Bar-Shalom R, Mashiach T, Barzilai E, Kornberg A, et al. Modification of initial therapy in early and advanced hodgkin lymphoma, based on interim PET\/CT is beneficial: a prospective multicentre trial of 355 patients. Br J Haematol. 2017;178(5):709\u201318.","journal-title":"Br J Haematol"},{"issue":"6","key":"15219_CR29","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1200\/JCO.2014.58.7543","volume":"33","author":"AJ Olszewski","year":"2015","unstructured":"Olszewski AJ, Shrestha R, Castillo JJ. Treatment selection and outcomes in early-stage classical hodgkin lymphoma: analysis of the National cancer data base. J Clin Oncol. 2015;33(6):625\u201333.","journal-title":"J Clin Oncol"},{"issue":"8","key":"15219_CR30","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1002\/ajh.25856","volume":"95","author":"SM Ansell","year":"2020","unstructured":"Ansell SM, Hodgkin lymphoma. A 2020 update on diagnosis, risk-stratification, and management. Am J Hematol. 2020;95(8):978\u201389.","journal-title":"Am J Hematol"},{"issue":"5","key":"15219_CR31","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1016\/j.ijrobp.2020.03.019","volume":"107","author":"A Wirth","year":"2020","unstructured":"Wirth A, Mikhaeel NG, Aleman BMP, Pinnix CC, Constine LS, Ricardi U, et al. Involved site radiation therapy in adult lymphomas: an overview of international lymphoma radiation oncology group guidelines. Int J Radiat Oncol Biol Phys. 2020;107(5):909\u201333.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"27","key":"15219_CR32","doi-asserted-by":"publisher","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","volume":"32","author":"BD Cheson","year":"2014","unstructured":"Cheson BD, Fisher RI, Barrington SF, Cavalli F, Schwartz LH, Zucca E, et al. Recommendations for initial evaluation, staging, and response assessment of hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014;32(27):3059\u201368.","journal-title":"J Clin Oncol"},{"key":"15219_CR33","first-page":"151","volume":"41","author":"A Ozturan","year":"2019","unstructured":"Ozturan A, Turgut M, Atay MH, Kelkitli E. The retrospective evaluation of hodgkin lymphoma cases and the effects of prognostic factors on survival: A Seven-year-experience. Age. 2019;41:151.","journal-title":"Age"},{"key":"15219_CR34","doi-asserted-by":"crossref","unstructured":"Geel JA, Chirwa TC, Rowe B, Eyal KC, Omar F, Stones DK, et al. Treatment outcomes of children with Hodgkin lymphoma between 2000 and 2010: First report by the South African Children\u2019s Cancer Study Group. Pediatr Blood Cancer. 2017;64:e26536.","DOI":"10.1002\/pbc.26536"},{"issue":"33","key":"15219_CR35","doi-asserted-by":"publisher","first-page":"4111","DOI":"10.1200\/JCO.2011.41.4193","volume":"30","author":"S Montoto","year":"2012","unstructured":"Montoto S, Shaw K, Okosun J, Gandhi S, Fields P, Wilson A, et al. HIV status does not influence outcome in patients with classical hodgkin lymphoma treated with chemotherapy using doxorubicin, bleomycin, vinblastine, and Dacarbazine in the highly active antiretroviral therapy era. J Clin Oncol. 2012;30(33):4111\u20136.","journal-title":"J Clin Oncol"},{"key":"15219_CR36","doi-asserted-by":"publisher","first-page":"507257","DOI":"10.1155\/2012\/507257","volume":"2012","author":"CA Jacobson","year":"2012","unstructured":"Jacobson CA, Abramson JS. HIV-Associated hodgkin\u2019s lymphoma: prognosis and therapy in the era of cART. Adv Hematol. 2012;2012:507257.","journal-title":"Adv Hematol"},{"issue":"9","key":"15219_CR37","doi-asserted-by":"publisher","first-page":"1469","DOI":"10.1093\/cid\/civ627","volume":"61","author":"C Besson","year":"2015","unstructured":"Besson C, Lancar R, Prevot S, Brice P, Meyohas MC, Marchou B, et al. High risk features contrast with favorable outcomes in HIV-associated hodgkin lymphoma in the modern cART Era, ANRS CO16 LYMPHOVIR cohort. Clin Infect Dis. 2015;61(9):1469\u201375.","journal-title":"Clin Infect Dis"},{"key":"15219_CR38","doi-asserted-by":"publisher","first-page":"e2100163","DOI":"10.1200\/GO.21.00163","volume":"8","author":"K Moahi","year":"2022","unstructured":"Moahi K, Ralefala T, Nkele I, Triedman S, Sohani A, Musimar Z, et al. HIV and hodgkin lymphoma survival: A prospective study in Botswana. JCO Glob Oncol. 2022;8:e2100163.","journal-title":"JCO Glob Oncol"},{"key":"15219_CR39","doi-asserted-by":"crossref","unstructured":"Antel K, Verburgh E. Lymphadenopathy in a tuberculosis-endemic area: diagnostic pitfalls and suggested approach. South Afr Med J. 2019;109(10).","DOI":"10.7196\/SAMJ.2019.v109i10.14361"},{"issue":"20","key":"15219_CR40","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","volume":"127","author":"SH Swerdlow","year":"2016","unstructured":"Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R, et al. The 2016 revision of the world health organization classification of lymphoid neoplasms. Blood. 2016;127(20):2375\u201390.","journal-title":"Blood"}],"updated-by":[{"DOI":"10.1186\/s12885-025-15452-7","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T00:00:00Z","timestamp":1768953600000}}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-15219-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-025-15219-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-15219-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T13:55:54Z","timestamp":1781618154000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12885-025-15219-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,25]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["15219"],"URL":"https:\/\/doi.org\/10.1186\/s12885-025-15219-0","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,25]]},"assertion":[{"value":"12 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 December 2025","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original article has been updated.","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 January 2026","order":8,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":9,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":10,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1186\/s12885-025-15452-7","URL":"https:\/\/doi.org\/10.1186\/s12885-025-15452-7","order":11,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Human Research Ethics Committee of the University of Cape Town (HREC 659\/2022) and GSH. A retrospective waiver of informed consent was granted for patients included in the HPR before 2018. Written informed consent was obtained for patients included from 2018 onwards. The study adhered to the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1813"}}